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Results for primary bypass versus primary
angioplasty/stent for intermittent claudication
due to superficial femoral artery occlusive disease
Jeffrey J. Siracuse, MD, Kristina A. Giles, MD, Frank B. Pomposelli, MD, Allen D. Hamdan, MD,
Mark C. Wyers, MD, Elliot L. Chaikof, MD, PhD, April E. Nedeau, MD, and
Marc L. Schermerhorn, MD, Boston, Mass
Background: Percutaneous transluminal angioplasty  stent (PTA/S) and surgical bypass are both accepted treatments
for claudication due to superficial femoral artery (SFA) occlusive disease. However, long-term results comparing these
modalities for primary intervention in patients who have had no prior intervention have not been reported. We report our
results with 3-year follow-up.
Methods: We reviewed all lower extremity bypass procedures at Beth Israel Deaconess Medical Center from 2001
through 2009 and all PTA/S performed from 2005 through 2009 for claudication. We excluded all limb salvage
procedures and included only those that were undergoing their first intervention for claudication due to SFA disease.
We recorded patient demographics, comorbidities, perioperative medications, TASC classification, and runoff.
Outcomes included complications, restenosis, symptom recurrence, reinterventions, major amputation, and mor-
tality.
Results: We identified 113 bypass grafts and 105 PTA/S of femoral-popliteal lesions without prior interventions.
Bypasses were above the knee in 62% (45% vein) and below the knee in 38% (100% vein). Mean age was 63 (bypass) versus
69 (PTA/S; P< .01).Mean length of stay (LOS) was 3.9 versus 1.2 days (P< .01). Bypass grafts were used less for TASC
A (17% vs 40%; P < .01) and more for TASC C (36% vs 11%; P < .01) and TASC D (13% vs 3%; P < .01) lesions. There
were no differences in perioperative (2% vs 0%; not significant [NS]) or 3-year mortality (9% vs 8%; NS). Wound infection
was higher with bypass (16% vs 0%; P < .01). None involved grafts. Bypass showed improved freedom from restenosis
(73% vs 42% at 3 years; hazard ratio [HR], 0.4; 95% confidence interval [CI], .23-.71), symptom recurrence (70% and
36% at 3 years; HR, 0.37; 95% CI, .2-.56), and freedom from symptoms at last follow-up (83% vs 49%; HR, 0.18; 95%
CI, .08-.40). There was no difference in freedom from reintervention (77% vs 66% at 3 years; NS). Multivariable analysis
of all patients showed that restenosis was predicted by PTA/S (HR, 2.5; 95% CI, 1.4-4.4) and TASC D (HR, 3.7; 95%
CI, 3.5-9) lesions. Recurrence of symptoms was similarly predicted by PTA/S (HR, 3.0; 95% CI, 1.8-5) and TASC D
lesions (HR, 3.1; 95% CI, 1.4-7). Statin use postoperatively was predictive of patency (HR, 0.6; 95% CI, .35-.97) and
freedom from recurrent symptoms (HR, 0.6; 95% CI, .36-.93).
Conclusions: Surgical bypass for the primary treatment of claudication showed improved freedom from restenosis and
symptom relief despite treatment of more extensive disease, but was associated with increased LOS and wound
infection. Statins improved freedom from restenosis and symptom recurrence overall. ( J Vasc Surg 2012;55:
1001-7.)
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extremity chronic arterial occlusive disease, affects 5% of
men and women between the ages of 55 and 74 and has an
increasing prevalence with age affecting up to 20% at age
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doi:10.1016/j.jvs.2011.10.1280.1-3 Many patients’ symptoms will improve or remain
table without intervention.1-4 Surgical bypass, either with
ative vein or prosthetic material, had been the standard
ntervention for refractory patients and had been done with
elatively low morbidity and with good results.5,6 How-
ver, as endovascular interventions for peripheral vascular
isease have become more common, percutaneous translu-
inal angioplasty  stent (PTA/S) has become increas-
ngly used as an intervention for claudicants.7-17 In fact, at
any institutions, it now has become the first-line interven-
ion.8,16 Comparisons between bypass grafts and PTA/S
how that PTA/S has good results in regard to primary
atency and symptom relief; however, endovascular inter-
entions have a higher recurrence of symptoms.9 Initially, it
as thought that advanced, TASC C-D, lesions should be
eserved for bypass.16,17 Recently, these have been shown
o be successfully treated endovascularly.18-20
The durability of PTA/S in comparison to surgical
ypass has previously been evaluated. However, many of
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April 20121002 Siracuse et althese analyses also include patients with rest pain and tissue
loss, with only a percentage of the patients being claudi-
cants.8,14 Studies looking specifically at claudicants do not
specifically exclude those who have had prior ipsilateral
interventions, nor do they stratify the lesions by Trans-
Atlantic Inter-Society Consensus (TASC) II classification,
exclude distal interventions, or include the perioperative
medication profile in the analyses.7,9-13
Our institution is a large referral center and university
hospital with a high volume of patients with lower extrem-
ity vascular disease. Our objective is to examine our expe-
rience in treating patients with claudication by surgical
bypass or endovascular intervention for primary treatment
of lesions in the femoral and popliteal region comparing
restenosis, our primary outcome, secondary restenosis,
symptom relief, reinterventions, limb loss, and death.
METHODS
We performed a retrospective cohort review of all pa-
tients undergoing interventions by the Division of Vascular
and Endovascular Surgery at Beth Israel Deaconess Medi-
cal Center with femoral-popliteal disease and claudication.
We individually reviewed the records of all surgical bypasses
from 2001 through 2009 and all endovascular interven-
tions from 2005 through 2009. Inclusion criteria included
a diagnosis of claudication, first-time ipsilateral interven-
tion, lesions in the femoral-popliteal region, and proce-
dures performed by vascular surgeons. Patients with more
distal interventions, rest pain, or tissue loss were excluded.
Demographics, perioperative medications, TASC II classi-
fication, runoff, comorbidities, perioperative complica-
tions, 30-day and late survival, recurrent symptoms, rein-
terventions, and limb loss were recorded. The choice of
intervention was surgeon-dependent at the time and varied
with acquisition of endovascular skills over time. Prosthetic
grafts were not used for below-knee popliteal bypass. The
choice of PTA/S intervention varied by surgeon prefer-
ence; however, in general, we use primary angioplasty
with selective stenting for residual stenosis 30% or
flow-limiting dissection. Routine statin use was intro-
duced over time. We generally treat with clopidogrel for 1
month and aspirin indefinitely. Technical success for
PTA/S was defined as 30% residual stenosis and no
flow-limiting dissection. For bypass, a patent graft at the
completion of the case and no significant defect in vein on
continuous-wave Doppler interrogation and angioscopy
were required for technical success.
Follow-up is variable, but in general, patients are seen
three to four times per year for 2 years and then one to two
times per year. Restenosis was evaluated by ultrasound or
angiography with 81% of patients receiving postoperative
ultrasounds.21 Duplex criteria for restenosis was 75% or
3.5-fold increase in peak systolic velocity. Intervention
was performed for symptomatic graft restenosis and asymp-
tomatic grafts that are threatened (peak systolic velocity
ratio 3.5-4, low graft velocities 30 cm/second). In
general, we do not reintervene for asymptomatic restenosis
post-PTA alone; however, we are more likely to reintervene tor an asymptomatic in-stent restenosis with peak systolic
elocity ratio of3.5-4. We are less likely to reintervene for
symptomatic restenosis if the disease was extensive and
estenosis was rapid, as we feel this has a low likelihood of
eriving a durable benefit. Symptom recurrence and devel-
pment of rest pain were determined by the attending
urgeon at follow-up with correlation to ankle-brachial
ndex (ABI) values. All angiographic images were reviewed
ith lesions graded according to the TASC II classification
ystem, with runoff vessels’ patency recorded according to
he Society for Vascular Surgery’s reporting standards.17
ategoric variables were analyzed by Pearson 2 and the
isher exact test.Median length of stay was compared using
he Wilcoxon rank-sum test. Treatment outcomes during
he course of follow-up were analyzed using Kaplan-Meier
ethodology, and time-to-failure curves were compared
ith the log-rank test. Univariate and multivariable Cox
egression models were used to assess predictor variables
or time-dependent outcomes. Statistical significance was
efined as P .05. All statistical tests were done using Stata
software (StataCorp, College Station, Tex).
ESULTS
Patient characteristics. There were a total of 113
ypass grafts and 105 PTA/S on 218 patients meeting our
nclusion and exclusion criteria. The average age in the
ypass group was 63 years, which was significantly younger
han the mean age of 69 years in the PTA/S group (P 
01). Congestive heart failure (CHF) was more common in
ypass patients (7% vs 0%; P  .01), while hypertension
HTN) was more common in PTA/S patients (66% vs
8%). There were no other differences in comorbidities and
atient characteristics between the two groups. Periopera-
ive aspirin and clopidogrel were used less in those having a
ypass than those undergoing PTA/S (77% vs 90%, P 
01; 23% vs 96%, P  .01). There was no significant
ifference in the use of warfarin or statins (4% vs 6%, NS;
2% vs 69%, NS). Bypass patients had a significantly higher
ate of -blocker use (75% vs 55%; P .01; Table I). Mean
ollow-up for bypass was an average of 25 months (median,
1 months; range, 1-91 months). For PTA/S, the mean
ollow-up was 18 months (median, 15 months; range,
1-49 months).
Patients treated with bypass had significantly fewer
ASC A lesions (17% vs 40%; P  .01) compared with the
TA/S group, while TASC B lesions were similar (34% vs
7%; Table II). There weremore TASCC (36% vs 11%; P
01) and TASC D (13% vs 3%; P  .01) lesions treated by
ypass. Patients undergoing a bypass were more likely to
ave disease-free runoff vessels to the foot than patients
ndergoing PTA/S (40% vs 27%; P .01). There were no
ther differences in the runoff between the two groups
Table III).
Perioperative outcomes. Technical success in the
TA/S and bypass groups was 100%. We had two patients
n the bypass group, one TASC C and one TASC D, who
ad a previously failed attempt at endovascular interven-
ion. There was a higher complication rate overall with
g
s
a
v
w
T
V
o
b
k
1
p
f
3
[
f
(
9
9
r
T
L
A
P
W
R
R
B
H
P
N
F
w
s
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 4 Siracuse et al 1003surgical bypass compared to PTA/S, mostly due to wound
infection (16% vs 0%; P  .01). However, the majority
(82%) were superficial wound infections that were treated
successfully with a short course of antibiotics, with the
remaining deeper infections (Szilagyi class II) not involving
the grafts (Table IV). Wound infections were distributed to
71% vein bypasses and 29% prosthetic bypass. All involved
veins were nonreversed that were harvested with a contin-
uous incision. Our perioperative antibiotic regimen has
Table I. Demographics and comorbidities
Bypass
(113 patients)
Primary
angioplasty/
stent (105
patients)
P
value
Age 63 (11.2) 69 (11.3) .01
Males 68% (77) 63% (66) NS
Coronary artery disease 39% (44) 41% (43) NS
Dialysis 0 (0) 0 (0) NS
Congestive heart failure 7% (8) 0 .01
Chronic obstructive
pulmonary disease 12% (14) 7% (7) NS
Diabetes mellitus 36% (41) 35% (37) NS
Hypertension 66% (75) 78% (82) .05
Previous stroke 8% (9) 9% (9) NS
Creatinine 1.0 (0.46) 1.07 (0.34) NS
Renal transplant 1% (1) 3% (3) NS
Former tobacco 36% (41) 44% NS
Current tobacco 29% (33) 22% (23) NS
Hyperlipidemia 59% (67) 50% (52) NS
Aspirin 77% 90% .01
Clopiogrel 23% 96% .01
Warfarin 4% 6% NS
Statin 62% 69% NS
-blocker 75% 55% .01
NS, Not significant.
Table II. TASC II classification of lesions
TASC II
Class
Bypass
(113 patients)
Primary
angioplasty/stent
(105 patients) P value
A 17% (19) 40% (42) .01
B 34% (38) 47% (49) NS
C 36% (40) 10% (11) .01
D 13% (16) 3% (3) .01
NS, Not significant; TASC, Trans-Atlantic Inter-Society Consensus.
Table III. Lower extremity runoff
Runoff
Bypass
(112 patients)
Primary
angioplasty/stent
(105 patients) P value
0 vessel disease 40% (45) 27% (28) .05
1 vessel disease 30% (34) 35% (37) NS
2 vessel disease 24% (27) 27% (28) NS
3 vessel disease 5% (6) 11% (12) NS
NS, Not significant.changed over time from cephazolin to vancomycin and wentamicin. Recently, after the scope of this study, we have
witched to cephazolin and vancomycin. Patients receiving
bypass had a significantly longer length of stay (LOS; 3.9
s 1.2; P  .01). Two bypass patients died after discharge
ithin 30 days, both of suspected myocardial infarctions.
here were no perioperative deaths in the PTA/S group.
ein was used 73% of the time and prosthetic material 27%
f the time in bypass patients. Sixty-two percent of the
ypasses were above the knee, and 38% were below the
nee. Vein was used in 45% of above-the-knee bypasses and
00% below-the-knee bypasses. Fifty-seven percent of the
atients in the PTA/S group were stented.
Long-term outcomes. Bypass had a higher freedom
rom restenosis when compared to PTA/S (73% vs 42% at
years; hazard ratio [HR], 0.4; 95% confidence interval
CI], .23-.71; Fig 1). Multivariable predictors of restenosis
or all patients in the study included PTA/S intervention
HR, 2.5; 95% CI, 1.4-4.4), TASC D lesions (HR, 3.7;
5% CI, 3.5-9), while statin use was protective (HR, 0.58;
5% CI, .35-.97). Three-year secondary freedom from
estenosis was 89% versus 79% (NS; Fig 2).When outcomes
able IV. Outcomes/complications
Bypass
Primary
angioplasty/
stent
P
value
ength of stay (mean days) 3.9 (2-11) 1.2 (1-3) .01
cute myocardial infarction 1% 0 NS
seudoaneurysm 0 4% NS
ound infection 16% 0% .01
enal failure 20% increase
in creatinine 3% 3% NS
eturn to operating room 3% 0 NS
leeding complication 2% 1% NS
ematoma 0 2% NS
ostoperative occlusion 2% 0 NS
S, Not significant.
ig 1. Improved freedom from restenosis with bypass (BPG)
hen compared with percutaneous transluminal angioplasty 
tent (PTA/S) (73% vs 42% at 3 years; HR, 0.4; 95% CI, .23-.71).ere stratified by TASC class, C-D lesions had a higher
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April 20121004 Siracuse et alfreedom from restenosis with bypass (HR, 4.2; 95% CI,
1.7-10.8; P  .01), with no significant difference seen for
TASC class A-B lesions. Freedom from complete occlusion
was 81% for bypass versus 85% for PTA/S at 3 years (NS).
Bypass patients were more likely to remain free from
claudication symptom recurrence at 3 years (70% vs 36% at
3 years; HR, 0.37; 95% CI, .2-.56; Fig 3) andmore likely to
have freedom from symptoms at last follow-up when com-
pared with PTA/S (83% vs 49% at 3 years; HR, 0.18; 95%
CI, .08-.40), taking into account subsequent interventions
(Fig 4). Predictors of symptom recurrence mirrored the
predictors of restenosis with PTA/S intervention (HR, 3.0;
95% CI, 1.8-5.0), TASC D lesions (HR, 3.1; 95% CI,
1.4-7), while statin use was again protective (HR, 0.6;
95% CI, .36-.93). ABI values preoperatively in patients
undergoing bypass were 0.64  0.15 and 0.69  0.13
for PTA/S (NS). Most recent postoperative ABIs for
Fig 2. No difference between bypass (BPG) and percutaneous
transluminal angioplasty stent (PTA/S) for secondary restenosis
at 3 years.
Fig 3. Improved freedom from recurrence of symptoms with
bypass (BPG) (70% and 36% at 3 years; HR, 0.37; 95% CI, .2-.56).
PTA/S, Percutaneous transluminal angioplasty  stent.those without symptom recurrence were 0.93  0.15 rompared with 0.68  0.18 for patients with symptoms
P  .01). TASC class, C-D lesions had a higher freedom
ecurrence of symptoms (HR, 3.9; 95% CI, 1.5-10.0; P 
01) with bypass compared with PTA/S as did TASC A-B
esions (HR, 2.5; 95% CI, 1.3-4.7; P  .01).
Freedom from rest pain at 3 years was 87% for bypass
nd 97% in the PTA/S (NS). Freedom from tissue loss at 3
ears was 98% for bypass compared with 99% for PTA/S
NS). There were no major lower extremity amputations in
ither group. Freedom from reintervention was similar
or bypass (77%) and PTA/S (66%) at 3 years (Fig 5). For
he 21 bypass patients with reinterventions, there were
2 endovascular interventions of grafts, no endovascular
nterventions of native vessels, 12 redo bypasses, nine
pen revisions, five femoral-to-anterior tibial bypasses, one
emoral-to-posterior tibial bypass, and one jump graft to an
nterior tibial bypass. For the 21 PTA/S patients with
ig 4. Improved freedom from symptoms at last follow-up with
ypass (BPG). PTA/S, Percutaneous transluminal angioplasty 
tent.
ig 5. There is no difference between reinterventions between
he two treatments at 3 years. BPG, Bypass; PTA/S, percutaneous
ransluminal angioplasty  stent.einterventions, there were 18 endovascular reinterven-
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Volume 55, Number 4 Siracuse et al 1005tions, four above-the-knee popliteal bypasses, two below-
the-knee popliteal bypasses, one femoral-to-posterior tibial
bypass, one femoral-to-anterior tibial bypass, and two en-
dovascular interventions of bypasses. No distal targets were
altered postoperatively in PTA/S patients with subsequent
below-the-knee bypass. Statin use, by multivariate analysis,
was associated with freedom from reintervention, but did
not reach statistical significance (HR, 0.6; 95% CI, .29-
1.03). Freedom from bypass at 3 years for PTA/S patients
was 87%. For PTA/S patients that subsequently underwent
bypass, half were TASC B and the remaining 50% were
evenly divided between TASC A and TASC C. Rest pain
developed in 13%, and none developed tissue loss. The
remainder had bypass for persistent claudication.
There were no differences in any of the primary out-
comes between vein versus prosthetic graft or above versus
below-the-knee bypass. There was also no difference in
outcomes between those that were stented and those that
were not.
Long-term survival (9% vs 8% at 3 years; NS) was not
significantly different for bypass versus PTA/S (Fig 6).
Multivariable predictors of mortality at 3 years include
chronic obstructive pulmonary disease (COPD; HR, 3.0;
95% CI, 1.1-8%), coronary artery disease (CAD; HR,
2.3; 95% CI, 1-5.2%), and diseased three-vessel runoff
(HR, 3.7; 95% CI, 1.1-11.9).
DISCUSSION
This is the largest study comparing first-time interven-
tions for claudicants. Those who had PTA/S had a signif-
icantly decreased length of stay (1.2 vs 3.9 days) and an
overall lower perioperative complication rate. However,
most of these complications are attributed to superficial
wound infections, the majority of which were adequately
treated with a course of antibiotics. Patients who had
PTA/S had significantly higher rates of restenosis and
recurrent symptoms. Surprisingly, this did not result in
Fig 6. There is no difference in mortality between bypass (BPG)
and percutaneous transluminal angioplasty  stent (PTA/S) at 3
years.more reinterventions as had been seen previously.9 This iay be due to the higher likelihood of our group reinter-
ening on a graft to maintain patency with a restenosis or a
ecurrence of symptoms and a more conservative attitude
oward multiple percutaneous reinterventions after early
estenosis. For the lesions with more extensive disease with
estenosis, there was thought to be a low likelihood of
ong-term success.
The younger average age of bypass patients may be
ttributed to selection bias since the less invasive procedure
ay have been offered to an older patient with claudication
ho previously would have had conservative medical treat-
ent. Not surprisingly, the patients in the PTA/S group
ad more TASC A lesions and fewer TASC C-D lesions.
TA/S has been increasingly used with favorable results
nd is being seen as a more viable option for TASC C-D
esions.18-20 However, in our study, bypass was superior to
TA/S for restenosis and recurrence of symptoms for
ASC C-D lesions. TASC D lesions were an independent
isk factor for restenosis and recurrence of symptoms over-
ll. Bypass failure of TASC D lesions may represent more
ggressive atherosclerotic disease in these patients and is
onsistent with our previous data in critical limb ischemia
atients showing a higher failure rate in TASCDpatients.22
he need for subsequent bypass after PTA/S may pose a
ong-term challenge, as distal targets can be altered from
ercutaneous interventions, although we did not see this in
ur study.23 There have been two randomized control trials
omparing Viabahn stents and prosthetic bypass with
ixed results in patient populations that included both
laudicants and those with critical limb ischemia.We do not
hink that the cost and need for larger sheath size mandates
heir use in our population with the limited data avail-
ble.24,25 Other comparisons between bypass and endovas-
ular intervention do not specify first ipsilateral interven-
ion, include those with chronic limb ischemia, do not
omment on TASC II classification, and do not include
erioperative medications.7,9,10-12
Statins have been increasingly used in cardiovascular
isease. They are thought to block inflammation and have a
eneficial effect independent of low-density lipoprotein
LDL) cholesterol reduction, halt atherosclerosis progres-
ion, stabilize plaques, and improve endothelial func-
ion.26,27 We saw a beneficial effect of statin use in our
opulation. Statin use was a positive predictive factor of
oth graft patency and symptom relief, while also trending
oward significance for freedom from reintervention.
enke et al and Abruzzese et al have shown that their lower
xtremity bypass patients, the majority of which were done
or limb threat, benefited by statin use in regard to graft
atency and limb salvage.28,29 Statin use has also been
hown to reduce mortality after bypass for critical limb
schemia, however, we did not see this in our population.30
n fact, statins alone have been shown to improve walking
istances and symptoms in claudication.31,32 There was no
ignificant difference in statin use between our two
roups, so this did not factor into one population having
n advantage over the other. Our results reinforce the
mportance of statins in cardiovascular disease and all
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should be on a statin if possible.
There are limitations to this study. It was a retrospective
single-center review with a small group of patients. Patients
were allocated to treatment based on surgeon preference
and which has changed over time. However, it is the largest
reported analysis of initial treatment of claudicants compar-
ing surgical bypass and PTA/S.
CONCLUSIONS
Our results show that, despite the national trend to-
ward endovascular intervention as the first-line treatment
for claudication, that surgical bypass remains an effective
and durable option for patients with low postoperative
morbidity and mortality. Statin use was beneficial in both
our treatment arms and their use should be standard in all
patients being assessed for claudication. Future work focus-
ing on costs and cumulative morbidity of primary and
subsequent interventions, particularly multiple sequential
vascular procedures or bypass after PTA/S needs to be
done.
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